{"id":34490,"date":"2025-05-30T18:26:23","date_gmt":"2025-05-30T10:26:23","guid":{"rendered":"https:\/\/flcube.com\/?p=34490"},"modified":"2025-05-30T18:26:24","modified_gmt":"2025-05-30T10:26:24","slug":"astellas-pharma-licenses-evopoints-cldn18-2-adc-for-global-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34490","title":{"rendered":"Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development"},"content":{"rendered":"\n

Japan-based Astellas Pharma Inc. (TYO: 4503<\/a>) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint’s XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.<\/p>\n\n\n\n

XNW27011: A Promising CLDN18.2 ADC<\/strong>
XNW27011 is a clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2, a protein overexpressed in several solid tumors. The drug is currently undergoing a Phase I\/II study in China, targeting CLDN18.2-positive solid tumor patients, including those with gastric cancer, gastroesophageal junction cancer, and pancreatic cancer. This partnership aims to accelerate the development of XNW27011 and bring it to patients globally.<\/p>\n\n\n\n

Strategic Collaboration to Advance Oncology Innovation<\/strong>
The collaboration between Astellas and Evopoint highlights the growing trend of international partnerships in oncology. By combining Astellas’ global reach and expertise in drug development with Evopoint’s innovative ADC technology, the two companies aim to address significant unmet needs in cancer treatment and improve outcomes for patients with CLDN18.2-positive tumors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint…<\/p>\n","protected":false},"author":1,"featured_media":34491,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,353,2896,1177],"class_list":["post-34490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-astellas-pharma","tag-evopoint-biosciences","tag-tyo-4503"],"yoast_head":"\nAstellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34490\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development\" \/>\n<meta property=\"og:description\" content=\"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34490\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-30T10:26:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-30T10:26:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development\",\"datePublished\":\"2025-05-30T10:26:23+00:00\",\"dateModified\":\"2025-05-30T10:26:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3002-1.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Astellas Pharma\",\"Evopoint Biosciences\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34490#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34490\",\"name\":\"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3002-1.webp\",\"datePublished\":\"2025-05-30T10:26:23+00:00\",\"dateModified\":\"2025-05-30T10:26:24+00:00\",\"description\":\"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34490\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3002-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3002-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34490#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development - Insight, China's Pharmaceutical Industry","description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34490","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development","og_description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.","og_url":"https:\/\/flcube.com\/?p=34490","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-30T10:26:23+00:00","article_modified_time":"2025-05-30T10:26:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34490#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34490"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development","datePublished":"2025-05-30T10:26:23+00:00","dateModified":"2025-05-30T10:26:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34490"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34490#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","keywords":["ADC \/ XDC","Astellas Pharma","Evopoint Biosciences","TYO: 4503"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34490#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34490","url":"https:\/\/flcube.com\/?p=34490","name":"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34490#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34490#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","datePublished":"2025-05-30T10:26:23+00:00","dateModified":"2025-05-30T10:26:24+00:00","description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint Biosciences, securing global development and commercialization rights for Evopoint's XNW27011, excluding mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the deal, Evopoint will receive an upfront payment of up to USD 130 million and is eligible for additional payments of up to USD 70 million in the near term. The agreement also includes development, regulatory, and commercial milestone payments totaling up to USD 1.34 billion, as well as royalties based on net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34490#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34490"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34490#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","width":1080,"height":608,"caption":"Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34490#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3002-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34490"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34490\/revisions"}],"predecessor-version":[{"id":34492,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34490\/revisions\/34492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34491"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}